New York, 12th August: Trump announces a deal with the US pharmaceutical company Moderna for millions of doses of potential coronavirus vaccine.
According to reports from international media, the Trump administration announced on Tuesday that it has reached a deal with the biotechnology company Moderna for 100 million doses of its potential coronavirus vaccine.
The agreement is for about $1.5 billion, which means that the government will pay about $15 per dose, and the vaccine will then be given to patients for free.
More than 700 people test positive for COVID-19
The Trump administration is signing similar other deals as it wants to fund multiple potential vaccines for COVID-19, in hope of having one dose ready by the end of this year.
President Trump announced the agreement from his White House press briefing as he seeks to highlight progress on a vaccine. Earlier in the day, he also met with the leaders of the Operation Warp Speed initiative aimed at developing a vaccine.
Russia announces first Coronavirus Vaccine
Of all the potential vaccines the government is funding, Trump said there is “tremendous promise in every single one of them and we have many of them and they’re years ahead of schedule.”
“The military is ready to go,” he added. “They’re ready to deliver a vaccine to Americans as soon as one is fully approved by the [Food and Drug Administration] and we’re moving very close to that approval.”
However, some Democrats and health officials are concerned that Trump may be putting too much pressure on the FDA to approve a vaccine too quickly, though the FDA has pledged it will follow the data.
COVID-19: Major breakthrough in the vaccine
Russia has previously claimed to have developed the coronavirus vaccine and takes a lead from countries around the world, including the United States, China, and the United Kingdom.
Clinical trials of the corona vaccine in Russia have entered the final stages and are expected to be approved in mid-August if effective.
Stay tuned to Baaghi TV for more updates!
You Probably Can’t Get COVID-19 Twice: The Latest on Antibodies